USA

The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.

The acquisition gives Lilly access to Ajax’s experimental therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers in which the bone marrow produces excessive blood cells.

The Illinois-based drugmaker said the new campus will span 185 acres near Research Triangle Park, one of the country’s leading life sciences clusters.

The NextAR Shoulder application forms part of Medacta’s broader NextAR Augmented Reality Surgical Platform, which supports multiple applications across joint replacement and spine surgery.

The collaboration will enhance the company’s ability to analyze complex datasets, identify promising drug candidates, and significantly reduce the time required to bring medications to patients.

Peak XV Partners leads investment round, with participation from Define Ventures and previous backers.

The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.